secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001104659-26-055679
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics reports Q1 2026 net loss $2.0M, FDA agrees to Phase 3 design for VCN-01 in PDAC
--------------------------------------------------------------------------------

- Cash and cash equivalents $14.4M as of March 31, 2026; cash runway into Q1 2027.
- FDA alignment on Phase 3 trial design for VCN-01 plus gemcitabine/nab-paclitaxel in metastatic PDAC.
- New VIRAGE Phase 2b data at AACR 2026 shows improved OS and PFS across subgroups including liver metastases.
- Compassionate use of VCN-01 in retinoblastoma started; Phase 2/3 trial expected first patient Dec 2026.
- R&D expenses fell 88% to $355K as VIRAGE trial completed; G&A rose 43% to $2.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/0001104659-26-055679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-055679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer